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Abstract
Background: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic
factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state
over time, but clinical studies of markers predicting the awakening potential of DTCs are lacking. Recently, experiments
have shown that NR2F1 (COUP-TF1) plays a key role in dormancy signaling.
Methods: We analyzed the NR2F1 expression in DTCs by double immunofluorescence (DIF) staining of extra cytospins
prepared from 114 BM samples from 86 selected DTC-positive breast cancer patients. Samples collected at two or
more time points were available for 24 patients. Fifteen samples were also analyzed for the proliferation marker Ki67.
Results: Of the patients with detectable DTCs by DIF, 27% had ≥ 50% NR2F1high DTCs, chosen a priori as the cut-off for
“dormant profile” classification. All patients with systemic relapse within 12 months after BM aspiration carried ≤ 1%
NR2F1high DTCs, including patients who transitioned from having NR2F1high-expressing DTCs in previous BM samples.
Of the patients with serial samples, half of those with no relapse at follow-up had ≥ 50% NR2F1high DTCs in the last BM
aspiration analyzed. Among the 18 relapse-free patients at the time of the last DTC-positive BM aspiration with no
subsequent BM analysis performed, distant disease-free intervals were favorable for patients carrying ≥ 50% NR2F1high
DTCs compared with those with predominantly NR2F1low DTCs (p= 0.007, log-rank). No survival difference was observed
by classification according to Ki67-expressing DTCs (p = 0.520).
Conclusions: Our study translates findings from basic biological analysis of DTC dormancy to the clinical situation and
supports further clinical studies of NR2F1 as a marker of dormancy.
Keywords: Disseminated tumor cells, DTC, Dormancy, NR2F1, Bone marrow, Breast cancer, Occult disease,
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Background
Breast cancer patients may experience relapse and sub-
sequent death from the disease many years after primary
treatment. This indicates an ability of occult cancer cells
to survive in a non- or slow-proliferating state, retaining
a potential for progression and proliferation at a later
time point [1, 2]. The window of time represented by such
minimal residual disease (MRD) represents a possibility
for therapeutic intervention to prevent development of
future metastasis rather than treat overt metastasis. How-
ever, the biology of the population of residual dissemi-
nated tumor cells (DTCs) is poorly understood. Large
studies have shown the presence of DTCs in bone marrow
(BM) to be a strong predictor of recurrence over the next
5 years [3, 4]. However, about 60% of the DTC-positive
patients remained relapse-free until the end of the
follow-up period. Consequently, there is an urgent need
for markers to disclose the functional state of DTCs and
evaluate their progression potential. Such markers may
help us to understand the biology of dormant DTCs in
patients and as decision-making tools for current and
new therapies.
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Our experimental model studies of DTC dormancy re-
vealed that NR2F1, an orphan nuclear receptor of the
retinoic acid receptor family, is commonly downregu-
lated in human cancer and metastatic tissues [5–7]. In
contrast, in a PDX model of squamous carcinoma,
NR2F1 was upregulated in the DTCs that entered spon-
taneous dormancy [6], and additional results suggested
that NR2F1 may pinpoint dormant DTCs in different
cancer types [6]. DTC analysis in the experimental
models indicated that when 40–50% of DTCs displayed
nuclear NR2F1, this correlated with quiescence markers,
other dormancy markers such as DEC2 and SOX9, and
lack of proliferation [6, 8]. In addition, a frequency of
less than 20% of DTCs positive for NR2F1 correlated
with a lack of expression of the above markers of dor-
mancy, quiescence, and proliferation. Metastatic and
local recurrence samples in head and neck squamous
cell carcinoma that clearly escaped dormancy showed
less than 5% of tumor cells positive for NR2F1 (supple-
menting data in [6]). Furthermore, dormant DTCs up-
regulated genes linked to NR2F1 signaling, including
several retinoic acid-regulated genes [6]. In prostate
cancer samples, we found that 43–47% of DTCs from
patients with no evidence of disease after many years of
relapse-free follow-up showed NR2F1 mRNA upregula-
tion, compared with 10% of the DTCs in advanced
prostate cancer [6]. Altogether, these results support
further testing of NR2F1 as a dormancy marker in soli-
tary DTCs from clinical samples, including assessment
of cut-off values to classify patients according to
NR2F1 expression.
Three Norwegian early breast cancer cohorts were
previously analyzed for DTCs in the BM [9–14] using the
standard immunocytochemical method (standard ICC)
[15, 16]. Clinical follow-up identified the presence of
DTCs to be a significant, independent predictor of un-
favorable outcome [9–12]. To explore the functional state
of the DTCs, we optimized double immunofluorescence
(DIF) protocols for detection of NR2F1 and Ki67 on DTCs
and analyzed selected BM samples from these three breast
cancer cohorts with comparison to clinical parameters.
Our study is the first to translate findings from basic bio-
logical mechanism analysis of DTC dormancy to the clin-
ical situation.
Materials and methods
Breast cancer patient cohorts
The patient material includes cytospins with BM mono-
nuclear cells (MNCs) from breast cancer patients in-
cluded in one of three different Norwegian studies in the
period from 1995 to 2008. An overview of the studies
and included patients is presented in Fig. 1, and below.
The NeoTax study enrolled 260 patients with stage III/
IV breast cancer between 1997 and 2003 and randomly
allocated them to treatment with paclitaxel or epirubicin,
with a crossover between treatment arms if there was no
response [9, 13, 14]. Stage IV patients were included only
if they harbored a locally advanced disease (T3/T4 and/or
Fig. 1 Clinical studies overview. Overview of the clinical studies, number of patients, and number of samples analyzed by DIF in the present
study. Bone marrow aspiration (BMA) time points are indicated, as well as therapy administered. *One patient had a BMA performed at an
unknown time point; however not harboring any disseminated tumor cells (DTC) by DIF. ER estrogen receptor
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N2/N3) with limited distant metastases. After chemother-
apy, mastectomy with axillary clearance was performed,
followed by radiotherapy and antihormonal therapy when
estrogen receptor (ER)-positive. BM aspirations for DTC
analysis were performed prior to the start of chemother-
apy (BM1), at surgery (BM2), and 12 months after
randomization (BM3).
The Oslo1 observational study enrolled 920 patients
with stage I/II breast cancer between 1995 and 1998,
and submitted them to standard adjuvant therapy, anti-
hormonal therapy, and radiotherapy according to Norwe-
gian guidelines at the time of the study. BM aspirations
for DTC analysis were performed at surgery (BM1), and
after 3 years of follow-up (for about one-third of the pa-
tients; BM2) [10, 11].
The SATT study [12, 17] enrolled 1121 patients with
operable breast cancer between 2003 and 2008. In
addition to chemotherapy, patients received antihormonal
therapy, radiotherapy, and from 2005 also herceptin if
HER2-positive, according to Norwegian guidelines at the
time of the study. Patients who had completed six cycles
of standard adjuvant fluorouracil, epirubicin, and cyclo-
phosphamide (FEC) chemotherapy underwent BM aspir-
ation 2 to 3 months (BM1) and 8 to 9 months (BM2) after
FEC. The presence of DTCs in BM was determined by im-
munocytochemistry. If one or more DTCs were present at
BM2, six cycles of docetaxel (100 mg/m2, once every
3 weeks) were administered, followed by DTC analysis 1
and 13 months after the last docetaxel infusion (BM3 and
BM4).
Preparation of bone marrow mononuclear cell samples
and cytospins
Bone marrow was aspirated in heparin (1000 IE/ml;
0.5 ml per 10 ml BM) from iliac crests bilaterally under
local anesthesia (5–10 ml per site) and pooled into one
tube. The samples were stored at room temperature
until processing within 24 h. The aspirates were diluted
1:1 in phosphate-buffered saline (PBS; Gibco, Life Tech-
nologies) and separated by density centrifugation using
Lymphoprep (Axis-Shield, Oslo, Norway). Mononuclear
cells were collected from the interphase layer, washed in
1% fetal calf serum in PBS (Gibco), and resuspended to
1 × 106 cells/mL. Cytospins were prepared by centrifuga-
tion of the BM MNCs down to poly-L-lysine-coated glass
slides (5 × 105 MNCs/slide) in a Hettich cytocentrifuge
(Tutlingen, Germany), air-dried at room temperature
overnight, and stored at −80 °C until immunostaining.
Patient material
For all the studies, the large majority of DTC-positive
samples had only one detectable DTC in the original
standard ICC analysis. A minority of the original sam-
ples contained ≥ 2–5 up to several thousand DTCs. For
the present study, stored frozen cytospins prepared in
parallel to the cytospins used for the initial (original)
analysis were used when available. For some samples, vi-
able BM MNCs stored in liquid nitrogen were thawed
and new cytospins were prepared. To increase the
chance of detecting DTCs in the study samples, we pri-
marily selected patients having ≥ 3 DTCs per 2 × 106 BM
MNCs by the original DTC analysis. However, patients
with 0–2 DTCs were also included. When available, we
prioritized BM from patients where successive samples
over time were available. For some patients, no more
spare BM was available for the present analysis. Nor-
mally, two cytospins containing in total 1 × 106 BM
MNCs with adequate staining quality were analyzed for
NR2F1 and for Ki67. The staining of samples and scor-
ing of Ki67 and NR2F1 were performed by EB and MCR
without access to the clinical database for the trials or
information about time to relapse.
Based on this, the present study included cytospins of
BM MNCs from a total of 86 patients categorized as
DTC-positive by the original “gold standard” DTC ana-
lysis performed prospectively within the original studies
(DTC-positivity in at least one original sample if more
than one BM aspiration was performed; ICC APAAP
technique, four cytospins, 2 × 106 BM MNCs analyzed)
[15, 16], of which 13 were included in Oslo1, 38 in the
NeoTax study, and 35 in the SATT study (Fig. 1). For 24
of these patients, successive analyses from two or three
time points were analyzed (20 at two time points and 4
at three time points). Samples from 11 patients with no
detectable DTCs by the original DTC analysis were also
included. In total, 127 samples were analyzed (all pre-
sented in Additional file 1: Table S1).
NR2F1/Ki67 and AE1AE3 double immunofluorescence
staining protocol
Double immunofluorescence was performed using the
broad-specter anticytokeratin (anti-CK) monoclonal anti-
bodies (mAbs) AE1/AE3 combined with anti-COUP TF1/
NR2F1 for expression of dormancy. From a selection of
the samples, parallel (additional) cytospins were available
and DIF was performed using anti-CK mAbs AE1/AE3
combined with the marker Ki67 for proliferation expres-
sion. Cytospins (0.5 × 106 MNCs/slide) were fixed for
12 min in methanol/acetone (1:1) at room temperature
and briefly air-dried, permeabilized in Triton X-100
(0.1% in PBS (DPBS Gibco-CaCl2/MgCl2)) for 7 min,
followed by a wash in PBS. The slides were then incu-
bated for 45 min with one of the following mAbs:
NR2F1 Anti-COUP TF1 (Abcam Ab 41,858; 10 μg/mL)
or anti-Ki67 clone MIB-1 (DAKO M7240; 1.15 μg/mL).
They were subsequently labelled with Alexa Fluor 488
goat anti-mouse IgG (H + L) (Molecular Probes 11029;
4 μg/mL) and incubated for 45 min. To block for
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cross-reactions (Ki67) the slides were then incubated
with a mouse mAb MOPC21 (Sigma-Aldrich M9269;
20 μg/mL) for 20 min. Finally, a combination of the
two anti-CK mAbs AE1 and AE3 (Chemicon Millipore
mAbs 1611/1612) were added, fluorescently labelled by
Zenon 555 (2 μg of the AE1/AE3 combination per slide
was labeled by the Zenon 555 mouse IgG labeling kit
(Life technologies Molecular Probes, Z25005) diluted to
20 μg/mL), and the slides were incubated for 45 min.
Slides were washed 2 × 5 min in PBS, then sealed with
ProLong Gold antifade reagent with DAPI (Life tech-
nologies P36931) and cover-slipped. Throughout the
protocol, the slides were washed 2 × 5 min in PBS after
each antibody incubation step. All antibodies were di-
luted in PBS/ 0.5% Tween20/ 5% normal goat serum.
Cytospins (0.5 × 106 MNCs/slide) spiked with 1% MCF7
or SKBR3 breast cancer cell line cells were used as
positive controls for the anti-CK staining and for
optimization of the DIF protocols. Among the normal
BM cells in the patient cytospins there were both
Ki67-positive cells and cells with 0–5 small NR2F1 sig-
nals (see a more detailed description below), serving as
internal positive controls for the NR2F1 staining.
Scoring of individual DTCs and NR2F1/Ki67 expression
Stained cells were identified by manual screening in a
Leica Microsystems DMI6000B fluorescence microscope,
using 20×, 40×, and 63× objectives. Only AE1/AE3-posi-
tive cells with a morphology compatible with tumor cells
were scored as DTCs [15, 16].
The definitions of DTC as either NR2F1low or NR2F1high
used in this study were determined prior to starting the
screening of the patient samples. When optimizing the
AE1AE3/NR2F1 DIF protocol we observed that a large ma-
jority (> 99%) of normal blood and BM MNCs showed
from zero up to two small NR2F1 nuclear localization sig-
nals (Additional file 2: Figure S1), and only occasionally did
normal BM cells harbor up to five small signals. In contrast,
in MCF7 and SKBR3 breast cancer cell line cells, and in test
patient samples harboring many DTCs, a range from zero
up to many, often large, irregular NR2F1 nuclear
localization signals were observed, often with an appear-
ance compatible with localization in the nucleoli (Add-
itional file 2: Figure S1); in some DTCs cytoplasmic signals
could also be observed. From our previous immunofluores-
cence experience in experimental models and cell lines in
vivo [6, 8] we have defined NR2F1high cells as cells with a
strong NR2F1 signal detected in all the nuclear area (Fig. 2a,
first row) or deposited as dotted or large irregular
nucleolar-like signals (Fig. 2a, second row). In proliferative
human and experimental tumors, the NR2F1 signal is ei-
ther negative (no signal at all) or a weak speckled signal, ex-
cept in certain areas that are hypoxic [8]. Based on these
data from both experimental studies and testing on MCF7
and SKBR3-spiked normal MNCs, we defined as
NR2F1lowa range of NR2F1 immunostaining from entirely
negative up to five small signals as seen in normal MNCs
(Additional files 2 and 3: Figures S1 and S2). A NR2F1
staining > 5 small signals and/or large signals (≥ 1), and/or
the presence of signal clusters defined DTCs as NR2F1high
(Fig. 2, Additional files 2 and 7: Figures S1 and S2).
A B
Fig. 2 Images of disseminated tumor cells (DTCs) stained by double immunofluorescence (AE1AE3/NR2F1 and AE1AE3/Ki67) and correlation
between Ki67 and NR2F1 expression. a DTCs from the BM of study patients analyzed by DIF. The strong and irregular cytoplasmic cytokeratin staining
(AE1AE3 antibody, in red fluorescence) identifies these cells as DTCs among the normal BM MNCs (AE1AE3-negative). The two upper rows show
NR2F1high DTCs with the presence of nuclear NR2F1 signal clusters (in green fluorescence; first row) or one large size NR2F1 signal (i.e., larger than the
size range observed in normal BM MNCs; second row). Third row shows two DTCs classified as NR2F1low containing only two (lower cell) or three
(upper cell) small NR2F1 signals, i.e., expression not exceeding what may be observed in normal BM MNCs. The bottom row shows two DTCs positive
for Ki67 (in green). b Comparison of the expression on DTC of NR2F1 versus the proliferation marker Ki67. Results from DIF analysis of Ki67/AE1AE3
versus NR2F1/AE1AE3, respectively, on 15 of the BM samples presented in Table 1, where additional cytospins were available for both analyses
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In accordance with the preclinical study data pre-
sented above, we chose to classify, a priori, samples with
≥ 50% NR2F1high DTCs as “dormant” and samples with
< 50% NR2F1high DTCs as “non-dormant”.
One of the patients with DTC-negative status accord-
ing to the original DTC analysis had one detectable
DTC by the DIF analysis and was not classified accord-
ing to “dormant” versus “non-dormant” status.
A Ki67-expressing DTC was defined as a cell exhibit-
ing nuclear immunostaining of Ki67.
Statistics
The association between DTC status/characteristics and
distant disease-free interval (DFI) was analyzed. Distant
DFI was defined as survival without distant breast cancer
recurrence or breast cancer death, and was constructed
using Kaplan-Meier curves with accompanied P values
obtained from a log-rank test. SPSS software was used
for statistical analysis.
Results
Bone marrow cytospins from 86 DTC-positive patients
identified by the original DTC staining procedure were
analyzed by DIF for cytokeratin (AE1/AE3) and NR2F1
expression as described in Materials and methods. An
overview of the BM aspiration (BMA) time points for
the included patients is presented in Fig. 1. From 24 of
these patients, BM samples at ≥ 2 time points were avail-
able for DIF analysis.
Cytokeratin-positive cells were classified as either
NR2F1high or NR2F1low according to the level and pat-
tern of expression (see Materials and methods, Fig. 2,
and Additional files 2 and 3: Figures S1 and S2).
Expression of Ki67 was analyzed in parallel with the
NR2F1 analyses on additional available cytospins from
15 DTC-positive patients (Table 1 and Fig. 2b). Of the
total 103 samples found to be DTC-positive (i.e., ≥ 1 de-
tectable DTC) by the original DTC staining procedure
(of 2 × 106 BM MNCs), 32 (31%) had cytokeratin-detectable
DTCs in the DIF analysis (of 1 × 106 BM MNCs) (Add-
itional file 4: Table S2), in accordance with an expected
lower sensitivity of this analysis. Twenty-four samples sub-
mitted to DIF had been concluded as DTC-negative by the
original DTC analysis. These included 13 samples from 11
patients with no original detectable DTCs. One of the sam-
ples had one detectable DTC by DIF, and the remaining 23
were DTC-negative (Additional file 4: Table S2). Data on
the original DTC-positive patients with DIF-positive results
and available clinicopathological characteristics are pre-
sented in Table 1.
The DIF analysis revealed that most of the analyzed
patients (24 out of 26) with CK-positive DTCs had ≥ 3
detectable cells and 16 had ≥ 10 DTCs in at least one
BM sample, representing a patient group with high risk
of metastasis (Table 1, Additional file 5: Table S3). In-
deed, 81% of the DTC-positive patients developed me-
tastasis after the BMA (n = 17) or had metastasis at time
of the BM aspiration (n = 4) (Table 1). Half (n = 13) of
the patients had > 1% of NR2F1high DTCs in at least one
BM sample and 26.9% (n = 7) had ≥ 50% NR2F1high
DTCs. The latter parameter (≥ 50% NR2F1high DTCs)
was chosen as the a priori cut-off for classifying the pa-
tient as having a “dormant profile” in accordance with
previous experimental studies [6, 8]. Of the samples with
detectable NR2F1high DTCs, the median proportion of
NR2F1high DTCs was 50%.
To explore changes in the expression of NR2F1 over
time and during treatment, DIF analysis was performed
on the 24 cases classified as DTC-positive in the
original DTC staining procedure and with available
samples from BM aspiration at two time points (see
Additional file 6: Figure S3 for the original DTC stain-
ing results). Of the cases analyzed, 16 received chemo-
therapy (± endocrine treatment), 5 endocrine treatment
only, and 3 no systemic treatment between the BM aspi-
rations (Additional file 7: Table S4). The number of
DIF-detected CK-positive DTCs and proportion of
NR2F1high DTCs are presented in Fig. 3. The results
showed different patterns of change and did not ap-
pear to be related to the type of adjuvant treatment
(Fig. 3). Three of the six patients with ≥ 50%
NR2F1high DTCs at the last BM analysis did not ex-
perience relapse. In contrast, 7 of 8 patients with ≤ 1%
NR2F1high DTCs at the last BM analysis had systemic
relapse or breast cancer death within 12 months (i.e.,
< 8 months) (Fig. 3b, c). Additional information on the
original DTC status, NR2F1 expression, and Ki67 ex-
pression of these patients are presented in Additional
file 8 (Table S5). All patients with systemic relapse or
breast cancer death within 12 months had ≤ 1%
NR2F1high DTCs (Table 1).
Table 2 presents the systemic relapse status among the
patients with 1 and ≥ 2 BM aspiration time points in
combination, according to the proportion of NR2F1-ex-
pressing cells in the DTC-positive cases (last positive
BM aspiration time point if > 1 performed). Of the pa-
tients with predominantly NR2F1low DTCs, 90% had,
or experienced, systemic relapse or breast cancer death
and 67% were recorded with bone metastasis. Similar
figures were observed for those with ≤ 1 NR2F1high DTCs.
In contrast, in those patients with ≥ 50% NR2F1high ex-
pressing DTCs, 57% had, or experienced, systemic relapse
and 29% were recorded with bone metastasis. Survival
analysis of all nonmetastatic patients at the time of last
DIF DTC-positive BM aspiration revealed a difference in
distant DFI (Fig. 4a; p = 0.023). Excluding patients ana-
lyzed for DIF-positive DTCs (with a negative result) at a
subsequent BMA time point (n = 18), 93% experienced
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systemic relapse/breast cancer death and 75% bone metas-
tasis among the patients with a “non-dormant” DTC clas-
sification. One of the four patients with ≥ 50% NR2F1high
DTCs (a “dormant” DTC classification) experienced bone
metastasis. Analysis of distant DFI among these 18 pa-
tients indicated a survival difference between the patients
classified by DTCs as having < 50% versus ≥ 50%
NR2F1high expressing cells (Fig. 4c; p = 0.007). A few pa-
tients had exceptionally high DTC numbers. A survival
analysis without the patients with ≥ 500 DTCs gave similar
results (p = 0.014; Additional file 9: Figure S4A). The
patients included in the NeoTax study had higher stages
(all with locally advanced disease) than the two other
cohorts. Excluding these patients from the survival
analysis did not change the results (p = 0.022; Additional
file 9: Figure S4B).
Limiting the analysis to only those with no
chemotherapy after the last BMA revealed similar
results, although the interpretation is restricted by
the low number of patients with ≥ 50% NR2F1high
DTCs (n = 2) (Table 2 and Additional file 10: Figure
S5; p = 0.091).
Table 2 NR2F1 expression and clinical outcome
Fraction of DTCs categorized as NR2F1high Distant metastasis (all) or
death from breast cancer (%)
Bone metastasisb (%)
All patientsa (n = 26) < 50% 0 to < 50% NR2F1high 17/19 (89.5) 10/15 (66.7)
0–1% NR2F1high 13/15 (86.7) 9/14 (64.3)
50–100% 4/7 (57.1) 2/7 (28.6)
Patients without metastasis prior to last
DTC-positive BMA and no negative DTC
status at subsequent BMA (n = 18)
< 50% 0 to < 50% NR2F1high 13/14 (92.9) 9/12 (75.0)
0–1% NR2F1high 11/12 (91.7) 8/11 (72.7)
50–100% 1/4 (25.0) 1/4 (25.0)
Patients with no metastasis at time point
for last DTC-positive BMA, no negative DTC
status at subsequent BMA, and no
chemotherapy after the BM analysis (n = 14)
< 50% 0 to < 50% NR2F1high 11/12 (91.7) 7/10 (70.0)
0–1% NR2F1high 9/10 (90.0) 6/9 (66.7)
50–100% 1/2 (50.0) 1/2 (50.0)
If analysis was performed at more than one time point, the last disseminated tumor cell (DTC)-positive sample is included
BMA bone marrow aspirate
aIncludes results from 4 patients with metastases detected before bone marrow (BM) analysis and 8 patients receiving chemotherapy after the BM analysis
bNo information on bone metastasis status was available from four patients in total
A B
C
Fig. 3 Disseminated tumor cell (DTC) status by DIF and NR2F1 expression in patients with bone marrow (BM) samples available at two time
points. Results of AE1AE3/NR2F1 DIF analysis performed on 24 patients classified as DTC-positive in the original DTC analysis, and with available
BM samples from two aspiration time points. The number of DIF cytokeratin-positive DTCs (a), the proportion of NR2F1high DTCs in patients with
DIF DTC-positive status at both BM aspiration (BMA) time points (b), and the proportion of NR2F1high DTCs in patients with DIF DTC-positive
status in the second but not the first BMA (c) are presented. The right sections of b and c show time to relapse or last observation and additional
clinical information for the patients presented in b and c. Chemo chemotherapy, N/A not applicable, neg negative, pos positive, Pt patient
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To compare the expression of NR2F1 and the prolifer-
ation marker Ki67, 1–2 additional cytospins from 15 of
the BM samples presented in Table 1 were analyzed by
Ki67/pan-cytokeratin DIF. NR2F1 and Ki67 expression
were not examined in the same DTCs (cytospins), and
therefore the combined expression pattern at the single
DTC level could not be addressed. The results showed
that the proportion of Ki67-positive DTCs was weakly
negatively correlated with the proportion of NR2F1high
DTCs (ρ = −0.466; p = 0.08; Fig. 2b), bearing in mind the
low number of cases analyzed for both Ki67 and NR2F1.
Survival was not different for patients classified into sub-
groups by Ki67 expression in DTCs using median di-
chotomization (Fig. 4b, p = 0.520; Fig. 4d, p = 0.464), or
by the same cut-off value as for NR2F1 (p = 0.753, data
not shown). The survival difference between patients
with NR2F1high and NR2F1low expressing DTCs were
similar if the analysis was restricted to only the patients
with samples analyzed for Ki67 (Additional file 11:
Figure S6; p = 0.019 and p = 0.026 for the same patient
categories as presented in Fig. 4).
Discussion
To further improve curative treatment of breast cancer,
we need to identify patients with MRD and characterize
the potential for MRD progression. To the best of our
knowledge, this is the first report exploring dormancy
marker profiling in DTCs in breast cancer patients. The
analysis of NR2F1 expression, a critical node in tumor
dormancy induction, can potentially differentiate be-
tween active occult tumor cells giving a risk for early
metastasis development and more long-term quiescent
DTCs. Such information may potentially contribute to
future clinical decisions based on minimal residual can-
cer detection and its state of activation.
We observed that the samples from patients with very
early systemic relapse (within 12 months) carried only
NR2F1low (non-dormant) DTCs in the last BM sample
A B
C D
Fig. 4 Survival analyses in relation to DTC dormancy profile and Ki67 status. Survival analyses (time to systemic relapse/breast cancer death) in
relation to NR2F1 (a,c) and Ki67 profile (b,d) of DTCs (at last DIF DTC-positive bone marrow (BM) aspiration). a,b Patients being nonmetastatic at
last DIF DTC-positive BMA. c,d Patients being nonmetastatic at last DIF DTC-positive BMA with no subsequent BM analysis performed.
Cum cumulative
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(≤ 1% NR2F1high DTCs). This included patients that
transitioned from having NR2F1high expressing DTCs to
a NR2F1low DTC state in consecutive samples (Fig. 3).
Likewise, longer disease-free interval/no detectable me-
tastases were indicated among patients with a presence
of predominantly NR2F1high DTCs. This was further
supported by the result from survival analysis of nonme-
tastatic patients showing a difference in metastasis-free
interval in subgroups according to NR2F1high expression
(Fig. 4a). However, the results should be interpreted with
caution due to the restricted number of patients ana-
lyzed and the heterogeneity in patient population and
treatment. Nevertheless, the data provide clinical sup-
port to the abundant previous experimental and some
clinical data (mRNA measurements) identifying NR2F1 as
a candidate marker for clinically relevant characterization
of MRD [6], and that NR2F1 may serve to identify DTC
long-term dormancy candidates even among patients
harboring larger number of DTCs. Indeed, the patients
studied were not selected to be obvious DTC dor-
mancy candidates by a long (many years) relapse-free
follow-up period. Most of the BM samples were col-
lected ≤ 3 years after diagnosis and were enriched for
cases with ≥ 5 DTCs, a known poor prognostic feature
[3, 4, 9–12]. Moreover, although the DTC Ki67 expres-
sion showed a weak negative correlation with NR2F1high
DTCs (Fig. 2b), no significant association with clinical out-
come was observed. This indicates that a proliferation
marker such as Ki67 is insufficient to characterize the
MRD cell population.
Since Ki67 detects all phases of the cell cycle, except
G0, it is possible that it may not accurately pinpoint true
dormant cells. In our experience, retinoblastoma protein
(pRb) and P-H3-negative, p27-positive cells are better indi-
cators of a quiescent NR2F1-positive DTC [6, 8, 18, 19].
The Ki67 result may place into the proliferative population
bin, cells that are in a G0/G1 boundary and arrested or
slow cycling. Furthermore, it may classify nonarrested cells
transiting through G0 as nonproliferative. In contrast,
NR2F1 expression is remarkably stable, epigenetically con-
trolled, and associated with a repressive chromatin state
observed in terminally senescent or differentiated cells [6].
These data suggest that NR2F1 marks a durable, more
long-lived phenotype of growth arrest. The presented data
and results from our experimental models also suggest that
NR2F1 is associated with cellular dormancy (quiescence)
and not tumor mass dormancy (representing a small can-
cer cell mass that cannot surpass a certain size) character-
ized by a balance between proliferation and apoptosis
where arrest is never observed. [20]. In our experience and
that of other investigators, the latter phenomenon is not
observed in solitary DTC dormancy [6, 8, 18, 19, 21, 22].
Published data also suggest that the mechanisms driving
solitary DTCs share a significant overlap with those
regulating adult stem cell quiescence [6, 20, 23], which is a
cellular dormancy mechanism. These mechanisms may ex-
plain the divergence between Ki67 and NR2F1, although
additional validation is needed because these markers
were not analyzed for in the same DTCs. Nevertheless,
results presented in this study and prior results strongly
support the concept [20] that lack of proliferation is
not the same as dormancy, but rather that proliferative
arrest is one characteristic of the dormancy program.
This underpins the need for markers that can identify
the biological key mechanisms for dormancy-associated
quiescence that are different from the absence of cell
cycle phase markers.
Improved techniques to assess the MRD population and
their dormant or reactivating state will be key to identify-
ing the risk of future metastasis despite undergoing stand-
ard treatment. This opens the way for testing new
treatments that prevent metastasis by inducing/enforcing
dormancy, and/or to eradicate MRD [2, 6]. Dormant can-
cer cells can evade chemotherapy and also express pluri-
potency genes that keep them in a long-term reawakening
probability state [6]. Retinoic acid and 5-azacitidine are
examples of dormancy-inducing/sustaining treatment
strategies, showing the ability to reprogram malignant
cells into dormancy and enforce dormancy programs in
already quiescent tumor cells [6, 7]. These drugs will be
tested in a clinical trial of prostate cancer patients at risk
of developing metastasis (Mount Sinai IRB no. 18–00226;
ClinicalTrials.gov identifier, NCT03572387).
Sustaining a dormancy phenotype could have life-saving
consequences. In line with this, patients with NR2F1 ex-
pression in a few DTCs appeared to have longer disease-
free survival in our study. This may suggest that those few
DTCs are indicative of at least two parameters that need
to be further investigated: first, that residual DTCs not de-
tected in the test clearly share the same phenotype as
those detected, and second, that the test seems to also
inform on patients that may have niches that are pro-dor-
mant and thus support dormancy of the residual DTCs
for longer time periods. The first possibility is supported
by abundant experimental evidence for a role of NR2F1 in
DTC dormancy through a microenvironmental and epi-
genetic program of regulation [6]. The second is less ex-
plored, but it is possible that some patients may be better
producers of dormancy-inducing cues as these are com-
monly signals involved in adult stem cell quiescence. Fur-
thermore, androgen deprivation treatment in prostate
cancer has been linked to upregulation of NR2F1 [24],
suggesting that certain commonly used therapies may in-
duce dormancy and cooperate in a long-term response by
affecting the DTCs and the host to enter a pro-dormancy
state. In breast cancer, response to tamoxifen was reported
to be associated with the presence of transforming growth
factor (TGF)β2, a dormancy-inducing factor [25, 26].
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Furthermore, a reduced androgen receptor signaling re-
sulted in TGFβ2 upregulation in the prostate and seminal
gland tissue [27]. Thus, future studies may not only focus
on detection of dormant DTCs, but also investigation of
whether the host is producing pro-dormancy cues.
Among all the patients included in the studies used as
the source for the current project [9–12] the majority of
those identified as DTC-positive had only one or two de-
tectable DTCs across the BMA time points (based on
the original analysis; NeoTax ≥ 75%, Oslo1 ≥ 87%, SATT
≥ 75%). The group of patients with such low numbers of
DTCs has the most favorable survival among the DTC-
positive cases [9, 28] and would also be expected to be
enriched in cases with quiescent DTCs. We attempted
to include both patients with originally high and low
numbers of DTCs in our analysis. However, in the ma-
jority of the samples, no DTCs were detectable by DIF
from patients with low DTC burden. In addition to the
Poisson distribution effect, this may be for several rea-
sons. Firstly, a reduced sensitivity of the DIF technique
compared with the standard (original) APAAP ICC
technique can be expected due to a stronger amplifica-
tion of the signals by the APAAP (three layers) than the
direct Xenon-labeling of the anti-CK antibody used in
the DIF protocol. Secondly, half the number of BM
MNCs (1 × 106) were available for the DIF analysis.
Thirdly, some of the DIF samples were prepared from
liquid nitrogen-frozen MNC suspensions, which in our
experience results in loss of tumor cells in some pa-
tients compared with cytospins prepared from fresh
BM. Further assessment and characterization of dor-
mancy in patients with very infrequent DTCs (i.e.,
below the detection level for our analysis) requires ana-
lysis of larger BM volumes in future studies, preferably
using enrichment techniques [29] or automated scan-
ning systems (http://rarecyte.com) combined with multi-
marker analysis. In parallel with DTC analysis, capturing
functional characteristics of circulating tumor cells (CTCs)
from high volumes of peripheral blood, for instance by a
multitube CellSearch analysis (https://www.cellsearchctc.
com/), leukapheresis-related techniques [30], or intravascu-
lar capturing devices [31, 32], would clarify whether assess-
ment of CTCs may be used for future dormancy studies.
Conclusions
Overall, we conclude that NR2F1 detection in BM DTCs
may be a promising tool to determine the phenotype of
DTCs and the prognosis of breast cancer patients. For de-
cades, DTC biology has been relegated primarily to the
area of enumeration and subsequent prognosis. Our
bench-to-bedside work reveals the first potential dor-
mancy marker that informs on the behavior of DTCs and
suggests that enumeration should be followed by pheno-
type information. Markers such as NR2F1 coupled to
DTC genetics and other host-derived indicators may pro-
vide a breakthrough in the management of MRD and me-
tastasis prevention.
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the DTCs have no NR2F1 signals and one has one small NR2F1 signal.
Surrounding BM MNCs have 0–1 NR2F1 signals of a similar size. (B, C)
One DTC with 2–3 small NR2F1 signals. Adjacent normal BM MNCs with
0–1 small NR2F1 signals. NR2F1high DTC (D, E): (D) Cluster of two DTCs
with coarse, partly confluent NR2F1 signals of varying sizes (signals in BM
MNCs not visualized because of not being in focus). (E) Cluster of 5 DTCs,
three of them defined as NR2F1high because of > 5 NR2F1 signals, partly
of large signal size. The remaining two DTCs, with no NR2F1 signals, are
assigned NR2F1low, as well as the adjacent normal BM MNCs with 0–1
small NR2F1 signals. (PDF 337 kb)
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Additional file 9: Figure S4. (A) Survival analyses (time to systemic
relapse/breast cancer death) in relation to NR2F1 profile of DTCs for
patients being nonmetastatic at the time point of last DIF DTC-positive
BMA and having no subsequent BM analyzed; patients harboring ≥ 500
DTC excluded. (B) Survival analyses (time to systemic relapse/breast
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Borgen et al. Breast Cancer Research  (2018) 20:120 Page 11 of 13
positive BMA, having no subsequent BM analyzed, and no chemotherapy after
last BMA. (PPTX 120 kb)
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